Prioritization of pandemic influenza vaccine: Rationale and strategy for decision making

Current Topics in Microbiology and Immunology

Volumn 333, Issue 1, 2009, Pages 495-507

  Schwartz, Benjamin ^a,b   Orenstein, Walter A ^c,d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CARE USA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; PANDEMIC INFLUENZA VACCINE; SEASONAL INFLUENZA VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG;

CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG DESIGN; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; MEDICAL ETHICS; PANDEMIC INFLUENZA; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA;

EID: 72049127925     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-92165-3_24     Document Type: Review

References (19)

1. Balicer RD, Omer SB, Barnerr DJ, Everly GS Jr (2006) Local public health workers' perceptions toward responding to an influenza pandemic. BMC Pub Health 6:99. doi:10.11186/1471-2458-6-99
2. Bresson J-L, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase 1 randomised trial. Lancet 367:1657-1664
3. CDC (2007) Community strategy for pandemic influenza mitigation http://www.pandemicflu. gov/plan/community/commitigation.html. Accessed 26 Feb 2008
4. Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437:209-214
5. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS (2006) Strategies for mitigating an influenza pandemic. Nature 442:448-452
6. Germann TC, Kadau K, Longini IM Jr, Macken CA (2006) Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 103:5935-5640
7. Heymann DL, Aylward RB (2006) Mass vaccination: when and why. Curr Top Microbiol Immunol 304:1-16
8. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons, E, Devaster J-M, Leroux-Roels G (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589
9. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W (2006) Safety and immu-nogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase 1 randomised controlled trial. Lancet 368:991-997
10. Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, Halloran ME (2005) Containing pandemic influenza at the source. Science 309:1083-1087
11. Monto AS, Davenport FM, Napier JA, Francis T Jr (1969) Effect of vaccination of a school-aged population upon the course of an A2/Hong Kong influenza epidemic. Bull World Health Org 41:537-542
12. National Infrastructure Advisory Council (2007) The prioritization of critical infrastructure in a pandemic influenza outbreak in the United States: final report and recommendations by the council. http://www.dhs.gov/xlibrary/ assets/niac/niac-pandemic-wg-v8-011707.pdf. Accessed 26 Feb 2008
13. Piedra PA, Gagliani MJ, Kozinetz CA, Riggs M, Griffith M, Fewlass C, Watts M, Hessel C, Cordova J, Glezen WP (2005) Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23:1540-1548
14. Public Engagement Pilot Project on Pandemic Influenza (2005) Citizen voices on pandemic flu choices. http://www.hhs.gov/nvpo/PEPPPI/ PEPPPICompleteFinalReport.pdf. Accessed 26 Feb 2008
15. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M (2001) The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344:889-896
16. Schwartz B, Wortley P (2006) Mass vaccination for annual and pandemic influenza. Curr Top Microbiol Immunol 304:131-152
17. Simonsen L, Clarke MJ, Schoenberger LB, Arden NH, Cox NJ, Fukuda K (1998) Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 178:53-60 The White House (2005) National strategy for pandemic influenza. http://www.whitehouse.gov/ homeland/pandemic-influenza. html. Accessed 26 Feb 2008
18. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A. (H5N1) vaccine. N Engl J Med 354:1343-1351
19. US Department of Health and Human Services (2005) Pandemic influenza plan: Appendix D. http://www.hhs.gov/pandemicflu/plan/appendixd.html. Accessed 26 Feb 2008